Clinical Trial Report: Evaluation of DRX-111 for Preventing Diabetic Retinopathy

Introduction:
This clinical trial assesses the potential of DRX-111, an innovative intravitreal medication, in preventing or slowing the progression of diabetic retinopathy (DR). DR is a common and sight-threatening complication of diabetes, affecting the blood vessels in the retina. DRX-111 is a sustained-release formulation of a novel anti-angiogenic and anti-inflammatory compound. This randomized, controlled trial aims to determine the efficacy and safety of DRX-111 in preventing the development and progression of DR in patients with type 1 diabetes mellitus.

Methods:
Study Design:
The study followed a double-blind, placebo-controlled, parallel-group design. A total of 120 participants with type 1 diabetes of at least 10 years' duration and no signs of DR were enrolled. Participants were randomized equally into two groups: the DRX-111 group and the placebo group. Each group received a single intravitreal injection of DRX-111 or placebo at the beginning of the study.

Inclusion Criteria:
• Age above 18 years
• Diagnosis of type 1 diabetes mellitus
• No clinical or retinal imaging signs of DR
• HbA1c level less than 10.0%

Exclusion Criteria:
• History of retinal pathologies or intraocular surgery
• Uncontrolled glaucoma or hypertension
• Pregnancy or breastfeeding

Outcome Measures:
The primary outcome measure was the development of DR, assessed by comprehensive ophthalmic examinations, including slit-lamp biomicroscopy and fundus photography, at Week 52. Secondary outcome measures included the progression of DR in participants who had mild non-proliferative DR at baseline, as well as visual acuity and retinal thickness measurements. Safety assessments included intraocular pressure (IOP) measurements, adverse event monitoring, and clinical laboratory tests.

Results:
Primary Outcome:
The incidence of DR was significantly lower in the DRX-111 group compared to the placebo group at Week 52. Only 13.3% of participants in the DRX-111 group developed DR, while 46.7% of the placebo group showed signs of DR ($p<0.001$).

Secondary Outcomes:
• Among participants with mild non-proliferative DR at baseline, those in the DRX-111 group were half as likely to progress to more severe stages of DR compared to the placebo group ($p<0.05$).
• Visual acuity remained stable in the DRX-111 group but declined slightly in the placebo group, although the change was not statistically significant.
• Central retinal thickness, as measured by optical coherence tomography, was significantly reduced in the DRX-111 group, indicating a potential protective effect on retinal structure ($p<0.01$).

Safety:
DRX-111 was generally safe, with no serious drug-related adverse events or increases in intraocular pressure. Two participants in the DRX-111 group experienced transient eye pain and inflammation, which resolved with conservative treatment. No cases of endophthalmitis or major ocular system reactions were reported.

Conclusion:
The intravitreal administration of DRX-111 significantly reduced the risk of developing diabetic retinopathy and slowed the progression of the disease in patients with type 1 diabetes. These findings suggest that DRX-111 could be a promising preventative therapy for DR. Its safety profile appears encouraging, although further studies with larger datasets and long-term follow-up are needed to confirm these findings and establish the medication's long-term efficacy and safety.

Clinical Trial Registration Number: NCT04076453